Last updated: April 25, 2026
What Is the Scope of JP2007522190, and Where Does It Sit in Japan’s Patent Landscape?
JP2007522190 is a Japan publication that derives from a PCT filing and enters the Japanese national phase. The document’s patentability and enforcement value in Japan depend on (i) the exact claim set published in JP2007522190, (ii) its prosecution history in Japan, (iii) whether it is maintained, and (iv) whether any later Japan continuations or divisionals exist that narrow or broaden the effective claim scope.
Scope and claims cannot be accurately reconstructed from the JP publication identifier alone. A claim chart, claim-by-claim mapping, freedom-to-operate boundaries, and landscape positioning require the actual text of JP2007522190 claims, claim dependencies, and the related family members’ claim sets. Without the claim text, any detailed “scope and claims” analysis would be speculative and therefore non-actionable for legal, regulatory, or investment decisions.
No complete and accurate claim-scope analysis is produced below because JP2007522190 claim text and family claim sets are not provided or retrievable in this context. The only safe deliverable is a framework of what must be evaluated, but that would still not meet the requirement for “hard data” on scope and claims.
What Claim Elements Determine the Patent Scope in Japan?
For a Japan drug patent publication like JP2007522190, scope is governed by the following claim mechanics:
| Scope driver |
What to extract from JP2007522190 |
How it affects enforcement in Japan |
| Independent claim language |
Drug substance definition, salts/solvates, polymorphs, substituents, stereochemistry |
Controls literal infringement and potential design-around space |
| Dependent claims |
Specific embodiments, preferred ranges, formulation details, dosing regimens |
Narrows coverage and defines fallback positions if independent claims are invalidated |
| Product vs method claims |
“A pharmaceutical composition” vs “A method of treating” |
Impacts enforcement routes and how generics can attempt to avoid infringement |
| Exceptions / disclaimers |
Carve-outs or negative limitations |
Can sharply constrain claim coverage even with broad genus terms |
| Priority and family ties |
Earliest priority, family members’ claim language |
Determines claim interpretation and obviousness/novelty attack surfaces |
How the Japan Landscape Is Typically Structured Around a Single Publication
A credible landscape for JP2007522190 in Japan is built from four layers:
- Direct family members (same priority set) with Japan equivalents (or amended claim scope).
- In-genre patents in Japan that claim:
- the same active ingredient (including salts and stereoisomers),
- the same formulation or dose form (tablet, capsule, depot, etc.),
- the same therapeutic use or patient subgroup,
- the same manufacturing process or polymorph selection.
- Opposition and invalidation footprint (Japan proceedings) that can narrow effective scope.
- Regulatory linkage that affects practical enforceability:
- patent listings in the regulatory system,
- any later settlement or consent orders that change filing strategy.
Why JP2007522190-Specific Claim Scope Cannot Be Produced
A detailed scope and claims analysis must quote or accurately paraphrase the exact claim terms from JP2007522190, including:
- all independent and dependent claims,
- claim formatting and dependency chains,
- specific numeric parameters (e.g., dosing mg, concentration ranges),
- defined chemical structures or genus definitions,
- formulation compositions and excipient lists (if claimed),
- disease/indication wording (if claimed as “use”).
Without the claim text, any attempt to identify those elements would be guesswork. That fails the “hard data and actionable insights” standard.
Key Takeaways
- JP2007522190 cannot be analyzed for its actual claim scope without the published claim text of JP2007522190 and its family claim sets.
- A complete Japan patent landscape positioning requires the same claim-level inputs to distinguish between:
- active-ingredient protection,
- formulation protection,
- use-method protection,
- and process or polymorph protection.
- Any detailed, claim-by-claim “scope and claims” or infringement boundary analysis would be speculative in the absence of the claims text.
FAQs
-
What information is required to perform a claim-scope analysis of JP2007522190 in Japan?
The full published claim set of JP2007522190 and any related family claim texts that enter Japan, including amendments that change claim meaning.
-
How is “scope” interpreted for Japanese drug patents like JP2007522190?
Primarily by the wording of independent claims, the narrowing effect of dependent claims, and the prosecution history that affects claim construction.
-
What does the Japanese landscape analysis focus on beyond the single publication?
Family members, nearby-in-genre patents in Japan (ingredient, formulation, use), and any invalidation or narrowing actions that change effective scope.
-
Can a patent landscape be produced without claim text?
Not at the level needed for freedom-to-operate and enforceability analysis; it must include claim-level comparisons.
-
What are the common design-around routes for competitors against drug patents in Japan?
Changing the protected ingredient form (salt/polymorph/stereochemistry), modifying the formulation/dose parameters, or avoiding the claimed therapeutic use and method steps.
References
- (No sources cited because JP2007522190 claim text and family documents were not provided in the prompt and are not available in this environment.)
